Journal ArticleAm Heart J · November 2024
Out-of-hospital cardiac arrest (OHCA) occurs in nearly 350,000 people each year in the United States (US). Despite advances in pre and in-hospital care, OHCA survival remains low and is highly variable across systems and regions. The critical barrier to im ...
Full textOpen AccessLink to itemCite
Journal ArticleJ Am Heart Assoc · August 6, 2024
BACKGROUND: Data on the benefits of cardiac resynchronization therapy (CRT) in patients with severe heart failure symptoms are limited. We investigated the relative effects of CRT in patients with ambulatory New York Heart Association (NYHA) IV versus III ...
Full textLink to itemCite
Journal ArticleJACC Adv · July 2024
Shared decision-making (SDM) and multidisciplinary team-based care delivery are recommended across several cardiology clinical practice guidelines. However, evidence for benefit and guidance on implementation are limited. Informed consent, the use of patie ...
Full textLink to itemCite
Journal ArticleHeart Rhythm · June 2024
BACKGROUND: Women might benefit more than men from cardiac resynchronization therapy (CRT) and do so at shorter QRS durations. OBJECTIVE: This meta-analysis was performed to determine whether sex-based differences in CRT effects are better accounted for by ...
Full textLink to itemCite
Journal ArticleHeart Rhythm · June 2024
The field of electrophysiology (EP) has benefited from numerous seminal innovations and discoveries that have enabled clinicians to deliver therapies and interventions that save lives and promote quality of life. The rapid pace of innovation in EP may be h ...
Full textLink to itemCite
Journal ArticleEur J Heart Fail · April 2024
AIMS: Patients with heart failure usually have several other medical conditions that might alter the effects of interventions. We investigated whether the burden of comorbidity modified the clinical response to cardiac resynchronization therapy (CRT). METH ...
Full textLink to itemCite
Journal ArticleAm Heart J · January 2024
BACKGROUND: Cardiac resynchronization therapy (CRT) reduces heart failure hospitalizations (HFH) and mortality for guideline-indicated patients with heart failure (HF). Most patients with HF are aged ≥70 years but such patients are often under-represented ...
Full textLink to itemCite
Journal ArticleJ Interv Card Electrophysiol · December 2023
BACKGROUND: Multiple randomized controlled trials (RCTs) have compared the success of antero-lateral vs. antero-posterior electrode position for cardioversion of atrial fibrillation (AF). However, due to small sample size and conflicting results of these R ...
Full textLink to itemCite
Journal ArticleAm Heart J · November 2023
Rate control is fundamental in the treatment of patients with atrial fibrillation (AF). The independent association of heart rate with outcomes and range of heart rate associated with best outcomes remains uncertain. We assessed the relationship between he ...
Full textLink to itemCite
Journal ArticleJ Cardiovasc Electrophysiol · November 2023
BACKGROUND: Traditional transvenous pacemakers are associated with worsening tricuspid valve function due to lead-related leaflet impingement, as well as ventricular dysfunction related to electromechanical dyssynchrony from chronic right ventricular (RV) ...
Full textLink to itemCite
Journal ArticleKidney Int Rep · November 2023
INTRODUCTION: Excessive dialytic potassium (K) and acid removal are risk factors for arrhythmias; however, treatment-to-treatment dialysate modification is rarely performed. We conducted a multicenter, pilot randomized study to test the safety, feasibility ...
Full textLink to itemCite
Journal ArticleAm Heart J · November 2024
Out-of-hospital cardiac arrest (OHCA) occurs in nearly 350,000 people each year in the United States (US). Despite advances in pre and in-hospital care, OHCA survival remains low and is highly variable across systems and regions. The critical barrier to im ...
Full textOpen AccessLink to itemCite
Journal ArticleJ Am Heart Assoc · August 6, 2024
BACKGROUND: Data on the benefits of cardiac resynchronization therapy (CRT) in patients with severe heart failure symptoms are limited. We investigated the relative effects of CRT in patients with ambulatory New York Heart Association (NYHA) IV versus III ...
Full textLink to itemCite
Journal ArticleJACC Adv · July 2024
Shared decision-making (SDM) and multidisciplinary team-based care delivery are recommended across several cardiology clinical practice guidelines. However, evidence for benefit and guidance on implementation are limited. Informed consent, the use of patie ...
Full textLink to itemCite
Journal ArticleHeart Rhythm · June 2024
BACKGROUND: Women might benefit more than men from cardiac resynchronization therapy (CRT) and do so at shorter QRS durations. OBJECTIVE: This meta-analysis was performed to determine whether sex-based differences in CRT effects are better accounted for by ...
Full textLink to itemCite
Journal ArticleHeart Rhythm · June 2024
The field of electrophysiology (EP) has benefited from numerous seminal innovations and discoveries that have enabled clinicians to deliver therapies and interventions that save lives and promote quality of life. The rapid pace of innovation in EP may be h ...
Full textLink to itemCite
Journal ArticleEur J Heart Fail · April 2024
AIMS: Patients with heart failure usually have several other medical conditions that might alter the effects of interventions. We investigated whether the burden of comorbidity modified the clinical response to cardiac resynchronization therapy (CRT). METH ...
Full textLink to itemCite
Journal ArticleAm Heart J · January 2024
BACKGROUND: Cardiac resynchronization therapy (CRT) reduces heart failure hospitalizations (HFH) and mortality for guideline-indicated patients with heart failure (HF). Most patients with HF are aged ≥70 years but such patients are often under-represented ...
Full textLink to itemCite
Journal ArticleJ Interv Card Electrophysiol · December 2023
BACKGROUND: Multiple randomized controlled trials (RCTs) have compared the success of antero-lateral vs. antero-posterior electrode position for cardioversion of atrial fibrillation (AF). However, due to small sample size and conflicting results of these R ...
Full textLink to itemCite
Journal ArticleAm Heart J · November 2023
Rate control is fundamental in the treatment of patients with atrial fibrillation (AF). The independent association of heart rate with outcomes and range of heart rate associated with best outcomes remains uncertain. We assessed the relationship between he ...
Full textLink to itemCite
Journal ArticleJ Cardiovasc Electrophysiol · November 2023
BACKGROUND: Traditional transvenous pacemakers are associated with worsening tricuspid valve function due to lead-related leaflet impingement, as well as ventricular dysfunction related to electromechanical dyssynchrony from chronic right ventricular (RV) ...
Full textLink to itemCite
Journal ArticleKidney Int Rep · November 2023
INTRODUCTION: Excessive dialytic potassium (K) and acid removal are risk factors for arrhythmias; however, treatment-to-treatment dialysate modification is rarely performed. We conducted a multicenter, pilot randomized study to test the safety, feasibility ...
Full textLink to itemCite
Journal ArticleAm J Cardiovasc Drugs · November 2023
BACKGROUND: There is evidence to suggest that colchicine reduces the risk of recurrent atrial fibrillation (AF) after catheter ablation; however, the tolerability and safety of colchicine in routine practice is unknown. METHODS: Patients undergoing cathete ...
Full textLink to itemCite
Journal ArticleHeart Rhythm · October 2023
BACKGROUND: Left ventricular (LV) lead implantation is often the most challenging aspect of cardiac resynchronization therapy (CRT) procedures; early studies reported implant failure rates in ∼10% of cases. OBJECTIVE: The purpose of this study was to defin ...
Full textLink to itemCite
Journal ArticleHeart Rhythm · September 2023
Cardiac physiologic pacing (CPP), encompassing cardiac resynchronization therapy (CRT) and conduction system pacing (CSP), has emerged as a pacing therapy strategy that may mitigate or prevent the development of heart failure (HF) in patients with ventricu ...
Full textLink to itemCite
Journal ArticleJ Cardiovasc Electrophysiol · September 2023
AIMS: To investigate the association of cardiac resynchronization therapy (CRT) on outcomes among participants with and without a history of atrial fibrillation (AF). METHODS: Individual-patient-data from four randomized trials investigating CRT-Defibrilla ...
Full textLink to itemCite
Journal ArticleJ Am Heart Assoc · August 15, 2023
Background There is uncertainty about the appropriate use of primary prevention implantable cardioverter-defibrillators (ICDs) among older patients with hypertrophic cardiomyopathy. Methods and Results Patients with hypertrophic cardiomyopathy who received ...
Full textLink to itemCite
Journal ArticlemedRxiv · July 6, 2023
Data on the benefits of cardiac resynchronization therapy (CRT) in patients with severe heart failure (HF) symptoms are limited. We investigated the relative effects of CRT in patients with ambulatory NYHA IV vs. III functional class at the time of device ...
Full textLink to itemCite
Journal ArticleAnn Intern Med · July 2023
Evidence for diagnosis and treatment of atrial fibrillation (AF) has expanded substantially since 2017, when In the Clinic last considered this subject. Direct oral anticoagulants have become the predominant therapy for thromboembolic disease, and antidote ...
Full textLink to itemCite
Journal ArticleAnn Intern Med · May 2023
BACKGROUND: Racial disparities in implantable cardioverter-defibrillator (ICD) implantation are multifactorial and are partly explained by higher refusal rates. OBJECTIVE: To assess the effectiveness of a video decision support tool for Black patients elig ...
Full textLink to itemCite
Journal ArticleKidney Med · May 2023
RATIONALE & OBJECTIVE: Treatment with certain QT interval-prolonging antibiotics is associated with a higher risk of sudden cardiac death among individuals with hemodialysis-dependent kidney failure. Concurrent exposure to large serum-to-dialysate potassiu ...
Full textLink to itemCite
Journal ArticleJ Palliat Med · April 2023
Background: Cardiac resynchronization therapy (CRT) improves quality of life (QOL) in heart failure (HF) patients with reduced ejection fraction. Clinicians may have difficulty choosing between CRT with a pacemaker (CRT-P) or a defibrillator (CRT-D) for ol ...
Full textLink to itemCite
Journal ArticleCirculation · March 7, 2023
BACKGROUND: Benefit from cardiac resynchronization therapy (CRT) varies by QRS characteristics; individual randomized trials are underpowered to assess benefit for relatively small subgroups. METHODS: The authors analyzed patient-level data from pivotal CR ...
Full textLink to itemCite
Journal ArticleStroke · March 2023
Atrial fibrillation (AF) is one of the strongest risk factors for ischemic stroke, which is a leading cause of disability and death. Given the aging population, increasing prevalence of AF risk factors, and improved survival in those with cardiovascular di ...
Full textLink to itemCite
Journal ArticleCirculation · February 14, 2023
BACKGROUND: The comparative real-world outcomes of older patients with atrial fibrillation (AF) treated with anticoagulation compared with left atrial appendage occlusion (LAAO) may be different from those in clinical trials because of differences in antic ...
Full textLink to itemCite
Journal ArticleJAMA Cardiol · February 1, 2023
IMPORTANCE: Only modest attention has been paid to the contributions of social determinants of health to atrial fibrillation (AF) risk factors, diagnosis, symptoms, management, and outcomes. The diagnosis of AF provides unique challenges exacerbated by the ...
Full textLink to itemCite
Journal ArticleCurr Probl Cardiol · November 2022
The trends of implantable cardioverter defibrillator (ICD) use in patients with a durable left ventricular assist device (LVAD) remain uncertain. We used the National Inpatient Sample to identify hospitalizations between 2009 and 2018 in which patients rec ...
Full textLink to itemCite
Journal ArticleHeart Rhythm · November 2022
There are many challenges in the current landscape of electrophysiology (EP) clinical and translational research, including increasing costs and complexity, competing demands, regulatory requirements, and challenges with study implementation. This review s ...
Full textLink to itemCite
Journal ArticleNephrol Dial Transplant · October 19, 2022
BACKGROUND: Hypokalemia is a risk factor for drug-induced QT prolongation. Larger serum-to-dialysate potassium gradients during hemodialysis (HD) may augment the proarrhythmic risks of selective serotonin reuptake inhibitors (SSRIs). METHODS: We conducted ...
Full textLink to itemCite
Journal ArticleKidney Int · October 2022
Azithromycin is an antibiotic with QT-prolonging potential commonly prescribed to individuals receiving hemodialysis. Hemodialysis patients have a high prevalence of clinical conditions, such as structural heart disease, that can enhance the pro-arrhythmic ...
Full textLink to itemCite
Journal ArticlePacing Clin Electrophysiol · August 2022
BACKGROUND: For cardiac resynchronization therapy (CRT), image-guided approaches targeting left ventricular (LV) lead placement at the site of latest mechanical activation had inconsistent outcomes. We examined evidence for improved CRT outcomes when LV le ...
Full textLink to itemCite
Journal ArticleAm J Manag Care · August 2022
OBJECTIVES: CMS' coverage with evidence development (CED) policy allows Medicare beneficiaries to access promising therapies and services while additional data are collected. CED program characteristics are mostly unreported, and qualities associated with ...
Full textLink to itemCite
Journal ArticleJ Card Fail · June 2022
Cardiac implantable electronic devices, including implantable cardioverter-defibrillators and therapy, are part of guideline-indicated treatment for a subset of patients with heart failure with reduced ejection fraction. Current technological advancements ...
Full textLink to itemCite
Journal ArticlePharmacoepidemiol Drug Saf · June 2022
PURPOSE: Polypharmacy is common in the hemodialysis population and increases the likelihood that patients will be exposed to clinically significant drug-drug interactions. Concurrent use of proton pump inhibitors (PPIs) with citalopram or escitalopram may ...
Full textLink to itemCite
Journal ArticleJAMA Netw Open · May 2, 2022
IMPORTANCE: Only about half of patients with atrial fibrillation (AF) who are at increased risk for stroke are treated with an oral anticoagulant (OAC), despite guideline recommendations for their use. Educating patients with AF about prevention of stroke ...
Full textLink to itemCite
Journal ArticleJ Card Fail · May 2022
AIM: The "2022 AHA/ACC/HFSA Guideline for the Management of Heart Failure" replaces the "2013 ACCF/AHA Guideline for the Management of Heart Failure" and the "2017 ACC/AHA/HFSA Focused Update of the 2013 ACCF/AHA Guideline for the Management of Heart Failu ...
Full textLink to itemCite
Journal ArticleJ Am Coll Cardiol · March 22, 2022
BACKGROUND: The subcutaneous (S-) implantable cardioverter-defibrillator (ICD) is an alternative to the transvenous (TV-) ICD that is increasingly implanted in younger patients; data on the safety and effectiveness of the S-ICD in older patients are lackin ...
Full textLink to itemCite
Journal ArticleJ Card Fail · March 2022
Heart failure (HF) continues to be a major contributor of morbidity and mortality for men and women alike, yet how the predisposition for, course and management of HF differ between men and women remains underexplored. Sex differences in traditional risk f ...
Full textLink to itemCite
Journal ArticleJ Cardiovasc Electrophysiol · March 2022
BACKGROUND: Cardiac implanted electronic device (CIED) pocket and systemic infection remain common complications with traditional CIEDs and are associated with high morbidity and mortality. Leadless pacemakers may be an attractive pacing alternative for ma ...
Full textLink to itemCite
Journal ArticleJACC Heart Fail · March 2022
OBJECTIVES: This study sought to assess the comparative effectiveness of cardiac resynchronization therapy with defibrillator (CRT-D) over implantable cardioverter-defibrillator (ICD) alone in older Medicare patients with heart failure with reduced ejectio ...
Full textLink to itemCite
Journal ArticleCirc Res · February 18, 2022
There is a growing appreciation for differences in epidemiology, treatment, and outcomes of cardiovascular conditions by sex. Historically, cardiovascular clinical trials have under-represented females, but findings have nonetheless been applied to clinica ...
Full textLink to itemCite
Journal ArticleEur Heart J Qual Care Clin Outcomes · January 5, 2022
AIMS: Older patients with atrial fibrillation (AF) are at risk of adverse outcomes, which is accentuated by comorbidities. We sought to examine the association between morbidity burden and the treatment of older AF patients. METHODS AND RESULTS: Using Dani ...
Full textLink to itemCite
Journal ArticleCardiol J · 2022
BACKGROUND: Many patients in the Sudden Cardiac Death in Heart Failure Trial (SCD-HeFT) had a significant improvement (> 10%) in the left ventricular ejection fraction (LVEF) during the course of the study, but the factors and outcomes associated with such ...
Full textLink to itemCite
Journal ArticleJAMA Cardiol · January 1, 2022
IMPORTANCE: Respiratory fluoroquinolone antibiotics are some of the most common medications with QT interval-prolonging potential prescribed to patients with hemodialysis-dependent kidney failure-individuals who have a very high risk of sudden cardiac deat ...
Full textLink to itemCite
Journal ArticleJ Interv Cardiol · 2022
AIM: To assess evidence for an image-guided approach for cardiac resynchronization therapy (CRT) that targets left ventricular (LV) lead placement at the segment of latest mechanical activation. METHODS: A systematic review of EMBASE and PubMed was perform ...
Full textOpen AccessLink to itemCite
Journal ArticleCJC Open · December 2021
Atrial fibrillation (AF) is the most common clinical arrhythmia, and it results in adverse outcomes and increased healthcare costs. Racial and ethnic differences in AF management, although recognized, are poorly understood. This review summarizes racial di ...
Full textLink to itemCite
Journal ArticleJAMA Cardiol · November 1, 2021
IMPORTANCE: Left atrial appendage occlusion (LAAO) has emerged as an alternative to anticoagulation for select patients with atrial fibrillation; however, women have been underrepresented in clinical trials of LAAO, and sex-specific subanalyses are limited ...
Full textLink to itemCite
Journal ArticleResuscitation · November 2021
BACKGROUND: Patients with sudden cardiac arrest occurring in the acute phase of myocardial infarction (MI-SCA) are believed to be at similar risk of death after revascularization compared with MI patients without SCA (MI-no SCA). Among patients with anteri ...
Full textLink to itemCite
Journal ArticleHeart Rhythm O2 · October 2021
BACKGROUND: Atrioventricular (AV)-synchronous single-chamber leadless pacing using a mechanical atrial sensing algorithm produced high AV synchrony in clinical trials, but clinical practice experience with these devices has not yet been described. OBJECTIV ...
Full textOpen AccessLink to itemCite
Journal ArticleJ Am Heart Assoc · August 17, 2021
There has been sustained focus on the secondary prevention of coronary heart disease and heart failure; yet, apart from stroke prevention, the evidence base for the secondary prevention of atrial fibrillation (AF) recurrence, AF progression, and AF-related ...
Full textLink to itemCite
Journal ArticleCardiovasc Digit Health J · August 2021
This collaborative statement from the Digital Health Committee of the Heart Rhythm Society provides everyday clinical scenarios in which wearables may be utilized by patients for cardiovascular health and arrhythmia management. We describe herein the spect ...
Full textLink to itemCite
Journal ArticleHeart · May 2021
AIMS: The ARISTOTLE (Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation) trial randomised patients with atrial fibrillation at risk of stroke to apixaban or warfarin. We sought to describe patients from ARISTOTLE who pr ...
Full textLink to itemCite
Journal ArticleCirculation · February 2, 2021
AIM: This executive summary of the valvular heart disease guideline provides recommendations for clinicians to diagnose and manage valvular heart disease as well as supporting documentation to encourage their use. METHODS: A comprehensive literature search ...
Full textLink to itemCite
Journal ArticleASAIO J · February 1, 2021
OptiVol (Medtronic PLC, Minneapolis, MN) is a diagnostic feature of some cardiac implantable electronic devices (CIEDs) based on changes in thoracic impedance (TI) over time. Changes in TI can predict heart failure (HF) hospitalizations and mortality in HF ...
Full textLink to itemCite
Journal ArticleCardiovasc Digit Health J · February 2021
BACKGROUND: Digital health is transforming healthcare delivery. OBJECTIVE: To compare the current digital health landscape in select groups of cardiac electrophysiology (EP) professionals prior to and during the COVID-19 era. METHODS: Two online surveys we ...
Full textLink to itemCite
Journal ArticleCirculation · January 26, 2021
Clinically recognized atrial fibrillation (AF) is associated with higher risk of complications, including ischemic stroke, cognitive decline, heart failure, myocardial infarction, and death. It is increasingly recognized that AF frequently is undetected un ...
Full textLink to itemCite
Journal ArticleN Engl J Med · January 14, 2021
BACKGROUND: The selective cardiac myosin activator omecamtiv mecarbil has been shown to improve cardiac function in patients with heart failure with a reduced ejection fraction. Its effect on cardiovascular outcomes is unknown. METHODS: We randomly assigne ...
Full textLink to itemCite
Journal ArticleAm J Cardiol · January 1, 2021
The purpose of this analysis was to assess implantable cardioverter-defibrillator (ICD) utilization and its association with mortality among patients ≥65 years of age after coronary revascularization. Patients in the National Cardiovascular Database Regist ...
Full textLink to itemCite
Journal ArticleProg Cardiovasc Dis · 2021
Background The role of late gadolinium enhancement (LGE) on cardiac magnetic resonance imaging (c-MRI) for predicting outcomes of patients with hypertrophic cardiomyopathy (HCM) has been debated. Methods We searched PubMed and Embase and various published ...
Full textLink to itemCite
Journal ArticleProg Cardiovasc Dis · 2021
BACKGROUND: Cardiac resynchronization therapy (CRT) has been demonstrated to improve heart failure (HF) symptoms, reverse LV remodeling, and reduce mortality and HF hospitalization (HFH) in patients with a reduced left ventricular (LV) ejection fraction (L ...
Full textLink to itemCite
Journal ArticleProg Cardiovasc Dis · 2021
Atrial Fibrillation (AF) and heart failure (HF) with reduced ejection fraction (HFrEF) frequently coexist, resulting in significant morbidity and mortality. Therapeutic options for patients with AF and HFrEF are limited due to few antiarrhythmic drug (AAD) ...
Full textLink to itemCite
Journal ArticleProg Cardiovasc Dis · 2021
Aortic stenosis is the most common valvulopathy requiring replacement by means of the surgical or transcatheter approach. Transcatheter aortic valve replacement (TAVR) has quickly become a viable and often preferred treatment strategy compared to surgical ...
Full textLink to itemCite
Journal ArticleHeart rhythm O2 · December 2020
The tools of digital health are facilitating a much-needed paradigm shift to a more patient-centric health care delivery system, yet our health care infrastructure is firmly rooted in a 20th-century model that was not designed to receive medical data from ...
Full textCite
Journal ArticleJ Am Heart Assoc · December 2020
Background Knowledge is scarce regarding how multimorbidity is associated with therapeutic decisions regarding oral anticoagulants (OACs) in patients with atrial fibrillation. Methods and Results We conducted a cross-sectional study of hospitalized patient ...
Full textOpen AccessLink to itemCite
Journal ArticleClin J Am Soc Nephrol · November 6, 2020
BACKGROUND AND OBJECTIVES: Patients on dialysis are at high risk of complications related to implantable cardioverter defibrillator (ICD) implantation; use of subcutaneous ICDs may be preferred over transvenous devices due to lower risk of bloodstream infe ...
Full textLink to itemCite
Journal ArticleAm Heart J · November 2020
UNLABELLED: The use of cardiac magnetic resonance imaging (c-MRI) in risk stratification for clinical outcomes of patients with ischemic cardiomyopathy (ICM) remains low. This systematic review investigated the prognostic value of myocardial fibrosis as as ...
Full textLink to itemCite
Journal ArticleAm Heart J · November 2020
BACKGROUND: Many studies showing underuse of oral anticoagulants (OACs) in patients with atrial fibrillation (AF) predated the advent of the non-vitamin K antagonist OACs. We retrospectively examined use of OACs in a large commercially insured population. ...
Full textLink to itemCite
Journal ArticleCurr Hypertens Rep · October 23, 2020
PURPOSE OF REVIEW: To highlight the indications, procedural considerations, and data supporting the use of stellate ganglion blockade (SGB) for management of refractory ventricular arrhythmias. RECENT FINDINGS: In patients with refractory ventricular arrhy ...
Full textOpen AccessLink to itemCite
Journal ArticleJ Interv Card Electrophysiol · October 2020
Ventricular arrhythmias are an important cause of morbidity and mortality and come in a variety of forms, from single premature ventricular complexes to sustained ventricular tachycardia and fibrillation. Rapid developments have taken place over the past d ...
Full textLink to itemCite
Journal ArticleJ Interv Card Electrophysiol · October 2020
Ventricular arrhythmias are an important cause of morbidity and mortality and come in a variety of forms, from single premature ventricular complexes to sustained ventricular tachycardia and fibrillation. Rapid developments have taken place over the past d ...
Full textLink to itemCite
Journal ArticleHeart Rhythm O2 · October 2020
BACKGROUND: Women seem to derive more benefit from cardiac resynchronization therapy (CRT) than men, even after accounting for the higher burden of risk factors for nonresponse often observed in men. OBJECTIVE: To assess for sex-specific differences in lef ...
Full textLink to itemCite
Journal ArticleHealthc (Amst) · September 2020
Patient-reported health data provide information for pragmatic clinical trials that may not be readily available from electronic health records or administrative claims data. In this report, we present key considerations for collecting patient-reported hea ...
Full textLink to itemCite
Journal ArticleHeart Rhythm O2 · August 2020
BACKGROUND: Diabetes mellitus (DM) is an independent risk factor for atrial fibrillation (AF). Few studies have compared clinical outcomes after catheter ablation between patients with and those without DM. OBJECTIVE: The purpose of this study was to compa ...
Full textOpen AccessLink to itemCite
Journal ArticleJ Am Heart Assoc · June 16, 2020
Background There are conflicting data regarding the benefit of primary prevention implantable cardioverter-defibrillators (ICDs) in patients with diabetes mellitus and heart failure (HF) with reduced ejection fraction. We aimed to assess the comparative ef ...
Full textLink to itemCite
Journal ArticleCirculation · June 9, 2020
The interrelationships between atrial fibrillation (AF) and heart failure (HF) are complex and poorly understood, yet the number of patients with AF and HF continues to increase worldwide. Thus, there is a need for initiatives that prioritize research on t ...
Full textLink to itemCite
Journal ArticleJAMA Cardiol · June 1, 2020
IMPORTANCE: Little is known about the utilization rates and outcomes of implantable cardioverter-defibrillator (ICD) and cardiac resynchronization therapy defibrillator (CRT-D) placement among patients with advanced heart failure (HF). OBJECTIVE: To examin ...
Full textLink to itemCite
Journal ArticleEur J Heart Fail · May 2020
AIMS: Implantable cardioverter-defibrillator (ICD) therapy reduces mortality in patients with heart failure and current guidelines advise implantation of ICDs in patients with a life expectancy of >1 year. We examined trends in all-cause mortality in patie ...
Full textLink to itemCite
Journal ArticleAm Heart J · May 2020
BACKGROUND: Although cardiac resynchronization therapy (CRT) is effective for some patients with heart failure and a reduced left ventricular ejection fraction (HFrEF), evidence gaps remain for key clinical and policy areas. The objective of the study was ...
Full textLink to itemCite
Journal ArticleEuropace · May 1, 2020
The field of observational studies or "real world studies" is in rapid development with many new techniques introduced and increased understanding of traditional methods. For this reason the current paper provides an overview of current methods with focus ...
Full textLink to itemCite
Journal ArticleHeart Rhythm · March 2020
BACKGROUND: Reports on the subcutaneous implantable cardioverter-defibrillator (S-ICD) cumulatively demonstrate a low rate of complications, but clinical experience with this technology is limited compared with transvenous devices. OBJECTIVE: The purpose o ...
Full textLink to itemCite
Journal ArticleEuropace · March 1, 2020
Ventricular arrhythmias are an important cause of morbidity and mortality and come in a variety of forms, from single premature ventricular complexes to sustained ventricular tachycardia and fibrillation. Rapid developments have taken place over the past d ...
Full textLink to itemCite
Journal ArticleCirculation · February 11, 2020
Catheter ablation has brought major advances in the management of patients with atrial fibrillation (AF). As evidenced by multiple randomized trials, AF catheter ablation can reduce the risk of recurrent AF and improve quality of life. In some studies, AF ...
Full textLink to itemCite
Journal ArticleAm Heart J · February 2020
Myocarditis is a major cause of sudden cardiac death (SCD) and dilated cardiomyopathy (DCM) in young adults. Cardiac magnetic resonance is the established tool for the diagnosis of myocarditis, and late gadolinium enhancement detected on cardiac magnetic r ...
Full textLink to itemCite
Journal ArticleAm Heart J · February 2020
BACKGROUND: Despite a higher prevalence of sudden cardiac death (SCD), black individuals are less likely than whites to have an implantable cardioverter defibrillator (ICD) implanted. Racial differences in ICD utilization is in part explained by higher ref ...
Full textLink to itemCite
Journal ArticleClin Cardiol · February 2020
Most implantable cardioverter defibrillators (ICDs) are implanted for the purpose of primary prevention of sudden cardiac death among older patients with heart failure with reduced ejection fraction. Shared decision-making prior to device implantation is g ...
Full textLink to itemCite
Journal ArticleJ Arrhythm · February 2020
BACKGROUND: Catheter ablation is an important rhythm control therapy in patients with atrial fibrillation (AF) with concomitant heart failure (HF). The objective of this study was to assess the comparative efficacy of AF ablation patients with ischemic vs ...
Full textOpen AccessLink to itemCite
Journal ArticleJ Arrhythm · February 2020
Ventricular arrhythmias are an important cause of morbidity and mortality and come in a variety of forms, from single premature ventricular complexes to sustained ventricular tachycardia and fibrillation. Rapid developments have taken place over the past d ...
Full textLink to itemCite
Journal ArticleCirculation · January 7, 2020
BACKGROUND: The use of nonsteroidal anti-inflammatory drugs (NSAIDs) with oral anticoagulants has been associated with an increased risk of bleeding. We investigated the risk of bleeding and major cardiovascular outcomes in patients with atrial fibrillatio ...
Full textLink to itemCite
Journal ArticleHeart Rhythm · January 2020
Ventricular arrhythmias are an important cause of morbidity and mortality and come in a variety of forms, from single premature ventricular complexes to sustained ventricular tachycardia and fibrillation. Rapid developments have taken place over the past d ...
Full textLink to itemCite
Journal ArticleHeart Rhythm · January 2020
Ventricular arrhythmias are an important cause of morbidity and mortality and come in a variety of forms, from single premature ventricular complexes to sustained ventricular tachycardia and fibrillation. Rapid developments have taken place over the past d ...
Full textLink to itemCite
Journal ArticleCardiovasc Digit Health J · 2020
BACKGROUND: Many digital health technologies capable of atrial fibrillation (AF) detection are directly available to patients. However, adaptation into clinical practice by heart rhythm healthcare practitioners (HCPs) is unclear. OBJECTIVE: To examine HCP ...
Full textLink to itemCite
Journal ArticleAm J Cardiol · November 1, 2019
Whether patients with atrial fibrillation (AF) and thyroid disease are clinically distinct from those with AF and no thyroid disease is unknown. Furthermore, the effectiveness of anticoagulation for prevention of AF-related thromboembolic events in patient ...
Full textLink to itemCite
Journal ArticlePacing Clin Electrophysiol · November 2019
BACKGROUND: Compared with medical therapy, catheter ablation of atrial fibrillation (AF) in patients with heart failure (HF) improves cardiovascular outcomes. Risk scores (CAAP-AF and APPLE) have been developed to predict the likelihood of AF recurrence af ...
Full textOpen AccessLink to itemCite
Journal ArticleJ Cardiovasc Electrophysiol · November 2019
BACKGROUND: Centers for Medicare and Medicaid Services has mandated the use of shared decision-making (SDM) for implantable cardioverter-defibrillator (ICD) implantation. SDM tools help facilitate quality SDM by presenting patients with balanced evidence-b ...
Full textLink to itemCite
Journal ArticleAm Heart J · November 2019
The subcutaneous implantable cardioverter defibrillator (S-ICD) is a completely extrathoracic device that has recently been FDA approved for the prevention of sudden cardiac death in select populations. Although the transvenous implantable cardioverter def ...
Full textLink to itemCite
Journal ArticleCirc Arrhythm Electrophysiol · September 2019
BACKGROUND: Despite the publication of several randomized clinical trials comparing catheter ablation (CA) with medical therapy (MT) in patients with atrial fibrillation (AF), the superiority of one strategy over another is still questioned by many. In thi ...
Full textLink to itemCite
Journal ArticleHeart Rhythm · September 2019
BACKGROUND: It is unclear whether physiologic pacing by either cardiac biventricular pacing (BiVP) or His bundle pacing (HisBP) may prevent adverse structural and functional consequences known to occur among some patients who receive right ventricular paci ...
Full textLink to itemCite
Journal ArticleJ Am Coll Cardiol · August 20, 2019
BACKGROUND: It is unclear whether physiologic pacing by either cardiac biventricular pacing (BiVP) or His bundle pacing (HisBP) may prevent adverse structural and functional consequences known to occur among some patients who receive right ventricular paci ...
Full textLink to itemCite
Journal ArticleEuropace · August 1, 2019
Ventricular arrhythmias are an important cause of morbidity and mortality and come in a variety of forms, from single premature ventricular complexes to sustained ventricular tachycardia and fibrillation. Rapid developments have taken place over the past d ...
Full textLink to itemCite
Journal ArticleJ Arrhythm · June 2019
Ventricular arrhythmias are an important cause of morbidity and mortality and come in a variety of forms, from single premature ventricular complexes to sustained ventricular tachycardia and fibrillation. Rapid developments have taken place over the past d ...
Full textLink to itemCite
Journal ArticleCirculation · May 14, 2019
BACKGROUND: Guidelines caution against the use of non-vitamin K antagonist oral anticoagulants in patients with extremely high (>120 kg) or low (≤60 kg) body weight because of a lack of data in these populations. METHODS: In a post hoc analysis of ARISTOTL ...
Full textLink to itemCite
Chapter · April 5, 2019
Interventional electrophysiology has enjoyed explosive growth in the use of new imaging and mapping technologies as well as the novel application of existing technologies. This chapter provides an overview of appropriateness in relation to the use of imagi ...
Full textCite
Journal ArticleJ Am Coll Cardiol · April 2, 2019
Secundum atrial septal defect (ASD) is the most common adult congenital heart defect and can present with wide variation in clinical findings. With the intention of preventing morbidity and mortality associated with late presentation of ASD, consensus guid ...
Full textLink to itemCite
Journal ArticleEur J Cardiovasc Nurs · April 2019
BACKGROUND: Atrial fibrillation is associated with stroke, yet approximately 50% of patients are not treated with guideline-directed oral anticoagulants (OACs). AIMS: Given that the etiology of this gap in care is not well understood, we explored decision- ...
Full textLink to itemCite
Journal ArticleJ Am Soc Nephrol · March 2019
BACKGROUND: Out-of-hospital cardiac arrest, the leading cause of death among patients on hemodialysis, occurs frequently within outpatient dialysis centers. Practice guidelines recommend resuscitation training for all dialysis clinic staff and on-site defi ...
Full textLink to itemCite
Journal ArticleCirculation · February 12, 2019
BACKGROUND: Modern cardiometabolic clinical trials often include cardiovascular death as a component of a composite primary outcome, requiring central adjudication by a clinical events committee to classify cause of death. However, sometimes the cause of d ...
Full textLink to itemCite
Journal ArticleClin Trials · February 2019
BACKGROUND: The US Food and Drug Administration's Sentinel Initiative is well positioned to support pragmatic clinical trials. FDA-Catalyst combines direct contact with health plan members and/or providers with data in the Sentinel infrastructure. Here, we ...
Full textLink to itemCite
Journal ArticleClin Cardiol · February 2019
BACKGROUND: When used in appropriately selected heart failure (HF) patients, cardiac resynchronization therapy (CRT) reduces mortality and hospitalization. It is not understood whether CRT implantation during hospitalization for HF is associated with simil ...
Full textLink to itemCite
Journal ArticleAm Heart J · February 2019
BACKGROUND: Patients with atrial fibrillation (AF) often have multi-morbidity, defined as ≥3 comorbid conditions. Multi-morbidity is associated with polypharmacy, adverse events, and frailty potentially altering response to anticoagulation. We sought to de ...
Full textLink to itemCite
Journal ArticleCirculation · December 11, 2018
BACKGROUND: Landmark studies have demonstrated the safety and efficacy of implantable cardioverter-defibrillators (ICDs) in selected stable ambulatory patients with heart failure (HF) with a reduced ejection fraction receiving optimal medical therapy. It i ...
Full textLink to itemCite
Journal ArticleAnn Intern Med · December 4, 2018
BACKGROUND: The comparative safety and effectiveness of treatments to prevent thromboembolic complications in atrial fibrillation (AF) remain uncertain. PURPOSE: To compare the effectiveness of medical and procedural therapies in preventing thromboembolic ...
Full textLink to itemCite
Journal ArticleThromb Haemost · December 2018
BACKGROUND: Atrial fibrillation (AF) is a common cardiac arrhythmia that increases the risk of stroke. Medical therapy for decreasing stroke risk involves anticoagulation, which may increase bleeding risk for certain patients. In determining the optimal t ...
Full textLink to itemCite
Journal ArticleCirculation · October 23, 2018
Objective To review the literature systematically and perform meta-analyses to address these questions: 1) Is there evidence that self-measured blood pressure (BP) without other augmentation is superior to office-based measurement of BP for achieving bette ...
Full textLink to itemCite
Journal ArticleCirculation · October 16, 2018
BACKGROUND: Atrial fibrillation is associated with an increased risk of death. High-sensitivity troponin T, growth differentiation factor-15, NT-proBNP (N-terminal pro-B-type natriuretic peptide), and interleukin-6 levels are predictive of cardiovascular e ...
Full textLink to itemCite
Journal ArticleEuropace · October 1, 2018
AIMS: Implantable cardioverter-defibrillators (ICDs) are key in the prevention of sudden cardiac death, but outcomes may vary by type of device or programming [single chamber (SC) vs. dual chamber (DC)] in patients without a bradycardia pacing indication. ...
Full textLink to itemCite
Journal ArticleAm Heart J · October 2018
BACKGROUND: Large variations exist in the care processes and outcomes for patients who experience in-hospital cardiac arrest (IHCA). We examined if Get With The Guidelines-Resuscitation (GWTG-R) participation duration was associated with improved care proc ...
Full textLink to itemCite
Journal ArticleCirc Heart Fail · October 2018
BACKGROUND: Stroke prophylaxis in patients with atrial fibrillation (AF) and heart failure (HF) in the era of direct oral anticoagulants is not well characterized. Using data from American Heart Association Get With The Guidelines-AFIB, we sought to evalua ...
Full textLink to itemCite
Journal ArticleAm Heart J · July 2018
BACKGROUND: Left ventricular ejection fraction (LVEF) is used to select patients for primary prevention implantable cardioverter defibrillators (ICDs). The relationship between baseline and long-term follow-up LVEF and clinical outcomes among primary preve ...
Full textLink to itemCite
Journal ArticleCirculation · June 5, 2018
BACKGROUND: Compared with transvenous implantable cardioverter defibrillators (ICDs), subcutaneous (S)-ICDs require a higher energy for effective defibrillation. Although ventricular fibrillation conversion testing (CT) is recommended after S-ICD implantat ...
Full textLink to itemCite
Journal ArticleEur J Heart Fail · June 2018
AIM: There is limited information on the outcomes after primary prevention implantable cardioverter-defibrillator (ICD) implantation in patients with heart failure (HF) and diabetes. This analysis evaluates the effectiveness of a strategy of ICD plus medic ...
Full textLink to itemCite
Journal ArticleHeart Rhythm · May 2018
BACKGROUND: Few studies have examined outcomes of catheter ablation for atrial fibrillation (AF) in patients with heart failure (HF) with preserved ejection fraction (HFpEF). OBJECTIVE: The purpose of this study was to compare outcomes of AF ablation in pa ...
Full textLink to itemCite
Journal ArticleAm Heart J · April 2018
BACKGROUND: Heart failure with preserved ejection fraction may be associated with chronotropic incompetence, but little is known about the incidence and prevalence of permanent pacemaker use in this population or factors associated with its use. METHODS: W ...
Full textLink to itemCite
Journal ArticleHeart Rhythm · April 2018
BACKGROUND: Compared with men, women have longer corrected QT (QTc) intervals, lower clearance of dofetilide, and higher rates of drug-induced torsades de pointes, but the dofetilide dosing algorithm is the same for men and women. OBJECTIVE: The purpose of ...
Full textLink to itemCite
Journal ArticleJ Am Coll Cardiol · March 13, 2018
BACKGROUND: Digoxin is widely used in patients with atrial fibrillation (AF). OBJECTIVES: The goal of this paper was to explore whether digoxin use was independently associated with increased mortality in patients with AF and if the association was modifie ...
Full textLink to itemCite
ConferenceEur J Heart Fail · March 2018
AIMS: The incidence of and factors associated with sudden cardiac death (SCD) early after an acute heart failure (HF) hospital admission have not been well defined. METHODS AND RESULTS: We assessed SCD and ventricular arrhythmias in the Acute Study of Clin ...
Full textLink to itemCite
Journal ArticleCard Electrophysiol Clin · March 2018
The implantable cardioverter defibrillator (ICD) is a life-saving therapy in various patient populations. Although data on the outcomes of initial ICD implants are abundant, data on ICD replacements, especially in patients with improved left ventricular (L ...
Full textLink to itemCite
Journal ArticleAm Heart J · February 2018
BACKGROUND: Outcomes research training programs should prepare trainees to successfully compete for research funding. We examined how early-career investigators' prior and desired training aligns with recently funded cardiovascular (CV) outcomes research. ...
Full textLink to itemCite
Journal ArticleAm Heart J · February 2018
BACKGROUND: Many young investigators are interested in cardiovascular (CV) outcomes research; however, the current training experience of early investigators across the United States is uncertain. METHODS: From April to November 2014, we surveyed mentees a ...
Full textLink to itemCite
Journal ArticleJACC Clin Electrophysiol · January 2018
OBJECTIVES: In this study, the authors sought to perform a meta-analysis of controlled studies assessing the relationship between left atrial appendage (LAA) electrical isolation (EI) and recurrent atrial fibrillation (AF). BACKGROUND: LAA triggers could p ...
Full textLink to itemCite
Journal ArticleJ Innov Card Rhythm Manag · January 2018
Some congenital heart diseases (CHDs) and inherited arrhythmia syndromes are associated with an increased risk of sudden cardiac death (SCD). Appropriate selection criteria for implantable cardioverter-defibrillator (ICD) implantation in these patients are ...
Full textOpen AccessLink to itemCite
Journal ArticleDiabetes Care · December 2017
OBJECTIVE: We evaluated the specific causes of death and their associated risk factors in a contemporary cohort of patients with type 2 diabetes and atherosclerotic cardiovascular disease (ASCVD). RESEARCH DESIGN AND METHODS: We used data from the Trial Ev ...
Full textLink to itemCite
ConferenceJ Cardiovasc Electrophysiol · November 2017
BACKGROUND: No precise tools exist to predict appropriate shocks in patients with a primary prevention ICD. We sought to identify characteristics predictive of appropriate shocks in patients with a primary prevention implantable cardioverter defibrillator ...
Full textLink to itemCite
Journal ArticleCirculation · October 10, 2017
BACKGROUND: Lead management is an increasingly important aspect of care in patients with cardiac implantable electronic devices; however, relatively little is known about long-term outcomes after capping and abandoning leads. METHODS: Using the 5% Medicare ...
Full textLink to itemCite
ConferenceAm Heart J · September 2017
BACKGROUND: Primary prevention implantable cardioverter defibrillator (ICD) reduce all-cause mortality by reducing sudden cardiac death. There are conflicting data regarding whether patients with more advanced heart failure derive ICD benefit owing to the ...
Full textLink to itemCite
Journal ArticleCurrent Cardiovascular Risk Reports · September 1, 2017
Purpose of Review: Although the risk of sudden cardiac death is high in patients with end-stage renal disease (ESRD), it is not clear if such patients benefit from the implantable cardioverter defibrillator (ICD). This paper reviews data on the risk of sud ...
Full textCite
Journal ArticleJ Am Heart Assoc · August 23, 2017
BACKGROUND: Prior studies have demonstrated a link between the metabolic syndrome and increased risk of cardiovascular mortality. Whether the metabolic syndrome is associated with sudden cardiac death is uncertain. METHODS AND RESULTS: We characterized the ...
Full textLink to itemCite
Journal ArticleJ Am Coll Cardiol · August 1, 2017
OBJECTIVES: To determine, using systematic review of the biomedical literature, whether pacing reduces risk of recurrent syncope and relevant clinical outcomes among adult patients with reflex-mediated syncope. METHODS: MEDLINE (through PubMed), EMBASE, an ...
Full textLink to itemCite
ConferenceAm Heart J · July 2017
OBJECTIVES: We examined trends in CRT utilization overall and by sex and race and to assess whether CRT use is associated with a reduction in HF hospitalization and mortality. BACKGROUND: It is unknown whether underutilization and race/sex-based difference ...
Full textLink to itemCite
Journal ArticleBlood · June 1, 2017
We investigated the frequency and characteristics of intracranial hemorrhage (ICH), the factors associated with the risk of ICH, and outcomes post-ICH overall and by randomized treatment. We identified patients with ICH from the overall trial population en ...
Full textLink to itemCite
Journal ArticleJAMA Cardiol · June 1, 2017
IMPORTANCE: Conflicting data have emerged on the efficacy of implantable cardioverter defibrillators (ICDs) for primary prevention of sudden cardiac death (primary prevention ICDs) in patients with nonischemic cardiomyopathy. OBJECTIVE: To investigate the ...
Full textLink to itemCite
Journal ArticleJACC Clin Electrophysiol · June 2017
OBJECTIVES: This analysis evaluated temporal trends and factors associated with the use of dual-coil implantable cardioverter-defibrillator (ICD) leads. BACKGROUND: Data suggest that dual-coil ICD leads are not associated with lower mortality and can be mo ...
Full textLink to itemCite
Journal ArticleJ Am Coll Cardiol · May 16, 2017
BACKGROUND: Data regarding cardiac resynchronization therapy (CRT) in patients with multiple comorbidities are limited. OBJECTIVES: This study evaluated the association of multiple comorbidities with the benefits of CRT over implantable cardioverter-defibr ...
Full textLink to itemCite
Journal ArticleJAMA Cardiol · May 1, 2017
IMPORTANCE: The Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation (ARISTOTLE) trial reported that apixaban therapy was superior to warfarin therapy in preventing stroke and all-cause death while causing significantly f ...
Full textLink to itemCite
Journal ArticleAm J Cardiol · May 1, 2017
Ventricular tachycardia (VT) is common in cardiomyopathy patients with an implantable cardioverter-defibrillator. This analysis evaluated antiarrhythmic medication use and change in use over time in patients with VT and structural heart disease. Query of M ...
Full textLink to itemCite
Journal ArticleCirculation · March 21, 2017
BACKGROUND: The risk of sudden cardiac death (SCD) in patients with heart failure after coronary artery bypass graft surgery (CABG) has not been examined in a contemporary clinical trial of surgical revascularization. This analysis describes the incidence, ...
Full textLink to itemCite
Journal ArticleAm J Cardiol · March 15, 2017
Implantable cardioverter defibrillators (ICD) and cardiac resynchronization therapy (CRT) reduce mortality in many patients with heart failure (HF), but the current use and effectiveness of ICD/CRT in patients with chronic kidney disease (CKD) are uncertai ...
Full textLink to itemCite
Journal ArticleTher Adv Cardiovasc Dis · March 2017
Atrial fibrillation is a common, costly and morbid cardiovascular arrhythmia. Stroke prevention remains the mainstay of treatment for atrial fibrillation, and the recent advent of novel oral anticoagulants with direct factor IIa or factor Xa inhibition has ...
Full textLink to itemCite
Journal ArticleJ Am Coll Cardiol · January 24, 2017
BACKGROUND: Clinical trials of implantable cardioverter-defibrillators (ICDs) for secondary prevention of sudden cardiac death were conducted nearly 2 decades ago and enrolled few older patients. OBJECTIVES: This study assessed morbidity and mortality of o ...
Full textLink to itemCite
Journal ArticleInt J Cardiol · January 15, 2017
BACKGROUND: Evidence supporting use of antithrombotic therapy in atrial fibrillation (AF) is based mainly on data from patients with permanent, persistent, or paroxysmal AF. Less is known about the risk following a new diagnosis of AF and the efficacy and ...
Full textLink to itemCite
Journal ArticleCirculation · January 3, 2017
BACKGROUND: Guidelines recommend that patients with low ejection fraction (EF) after myocardial infarction (MI) have their EF reassessed 40 days after MI for implantable cardioverter-defibrillator (ICD) candidacy. This study examines rates of EF reassessme ...
Full textLink to itemCite
Journal ArticleJACC Clin Electrophysiol · January 2017
OBJECTIVES: This study sought to define the characteristics and risks of death of patients receiving a physician-designated secondary prevention implantable cardioverter-defibrillator (ICD) in contemporary clinical practice. BACKGROUND: Data on utilization ...
Full textLink to itemCite
Journal ArticleCirculation · November 22, 2016
BACKGROUND: A prolonged PR interval is common among cardiac resynchronization therapy (CRT) candidates; however, the association between PR interval and outcomes is unclear, and the data are conflicting. METHODS: We conducted inverse probability weighted a ...
Full textLink to itemCite
Journal ArticleJAMA Cardiol · November 1, 2016
IMPORTANCE: Trends and in-hospital outcomes associated with early adoption of the subcutaneous implantable cardioverter defibrillator (S-ICD) in the United States have not been described. OBJECTIVES: To describe early use of the S-ICD in the United States ...
Full textLink to itemCite
Journal ArticleCirculation · November 1, 2016
Advances in the field of defibrillation have brought to practice different types of devices that include the transvenous implantable cardioverter-defibrillator (ICD) with or without cardiac resynchronization therapy, the subcutaneous ICD (S-ICD), and the w ...
Full textLink to itemCite
Journal ArticleJ Interv Card Electrophysiol · October 2016
The evolving healthcare environment demands optimally measured quality of care. Performance measures are increasingly being used for quality improvement, public reporting, and reimbursement determinations. The National Quality Forum has created rigorous cr ...
Full textLink to itemCite
Journal ArticleJAMA Cardiol · September 1, 2016
IMPORTANCE: In the Apixaban for Reduction of Stroke and Other Thromboembolic Complications in Atrial Fibrillation (ARISTOTLE) trial, the standard dose of apixaban was 5 mg twice daily; patients with at least 2 dose-reduction criteria-80 years or older, wei ...
Full textLink to itemCite
Journal ArticleCirculation · August 16, 2016
BACKGROUND: Previous studies have found that women and black patients eligible for a primary prevention implantable cardioverter-defibrillator (ICD) are less likely than men or white patients to receive one. METHODS: We performed an observational analysis ...
Full textLink to itemCite
Journal ArticleHeart Rhythm · August 2016
Catheter ablation of ventricular tachycardia (VT) has evolved in recent years, especially in patients with ischemic heart disease. Data from prospective studies show that VT catheter ablation reduces the risk of recurrent VT; however, there is a paucity of ...
Full textLink to itemCite
Journal ArticleCirc Arrhythm Electrophysiol · July 2016
BACKGROUND: Patients with an unused or malfunctioning implantable cardioverter-defibrillator (ICD) lead may have the lead either abandoned or explanted; yet there are limited data on the comparative acute and longer-term safety of these 2 approaches. METHO ...
Full textLink to itemCite
Journal ArticleCirc Heart Fail · June 2016
BACKGROUND: Atrial fibrillation is common in patients with heart failure, but outcomes of patients with both conditions who receive cardiac resynchronization therapy with defibrillator (CRT-D) compared with an implantable cardioverter-defibrillator (ICD) a ...
Full textLink to itemCite
Journal ArticleAm Heart J · May 2016
AIMS: History of bleeding strongly influences decisions for anticoagulation in atrial fibrillation (AF). We analyzed outcomes in relation to history of bleeding and randomization in ARISTOTLE trial patients. METHODS AND RESULTS: The on-treatment safety pop ...
Full textLink to itemCite
Journal ArticleCirculation · April 5, 2016
OBJECTIVE: To review the literature systematically to determine whether noninvasive or invasive risk stratification, such as with an electrophysiological study of patients with asymptomatic pre-excitation, reduces the risk of arrhythmic events and improves ...
Full textLink to itemCite
Journal ArticleJ Am Coll Cardiol · April 5, 2016
OBJECTIVE: To review the literature systematically to determine whether noninvasive or invasive risk stratification, such as with an electrophysiological study of patients with asymptomatic pre-excitation, reduces the risk of arrhythmic events and improves ...
Full textLink to itemCite
Journal ArticleHeart Rhythm · April 2016
OBJECTIVE: To review the literature systematically to determine whether noninvasive or invasive risk stratification, such as with an electrophysiological study of patients with asymptomatic pre-excitation, reduces the risk of arrhythmic events and improves ...
Full textLink to itemCite
Journal ArticleJAMA Cardiol · April 1, 2016
IMPORTANCE: In the current therapeutic era, the risk for sudden cardiac death (SCD) after non-ST-segment elevation acute coronary syndrome (NSTE ACS) has not been characterized completely. OBJECTIVE: To determine the cumulative incidence of SCD during long ...
Full textLink to itemCite
Journal ArticleJAMA Cardiol · April 1, 2016
IMPORTANCE: Survival rates after in-hospital cardiac arrest (IHCA) vary significantly among US centers; whether this variation is owing to differences in IHCA care quality is unknown. OBJECTIVE: To evaluate hospital-level variation to determine whether hos ...
Full textLink to itemCite
Journal ArticleJ Interv Card Electrophysiol · March 2016
BACKGROUND: Patients with ischemic heart disease may have implantable cardioverter defibrillators (ICDs) implanted for primary or secondary prevention of sudden cardiac death. Although ICD shocks can be life saving, in some patients, they have been associa ...
Full textLink to itemCite
Journal ArticleCirculation · February 16, 2016
Two guidelines from the American College of Cardiology (ACC), the American Heart Association (AHA), and collaborating societies address the risk of aortic dissection in patients with bicuspid aortic valves and severe aortic enlargement: the "2010 ACCF/AHA/ ...
Full textLink to itemCite
Journal ArticleHeart Rhythm · February 2016
Physicians are in an excellent position to significantly contribute to medical device innovation, but the process of bringing an idea to the bedside is complex. To begin to address these perceived barriers, the Heart Rhythm Society convened a forum of stak ...
Full textLink to itemCite
Journal ArticleInt J Cardiol · January 1, 2016
BACKGROUND: Comorbid chronic obstructive pulmonary disease (COPD) is associated with poor outcomes among patients with cardiovascular disease. The risks of stroke and mortality associated with COPD among patients with atrial fibrillation are not well under ...
Full textLink to itemCite
Journal ArticleAm Heart J · January 2016
The MDEpiNet is a public-private partnership between the US Food and Drug Administration's Center for Devices and Radiological Health and participating partners. The PASSION program is an MDEpiNet-sponsored program that aims to demonstrate the goals of MDE ...
Full textLink to itemCite
Journal ArticleAm Heart J · January 2016
UNLABELLED: Non-ST-segment myocardial infarction (NSTEMI) can be complicated by high-degree atrioventricular (AV) block, asystole, or electromechanical dissociation (EMD), but these events are not well characterized in the contemporary era. This analysis a ...
Full textLink to itemCite
Journal ArticleCirc Heart Fail · January 2016
BACKGROUND: Clinical trials of implantable cardioverter defibrillators (ICDs) for primary prevention enrolled a limited number of women. We sought to examine clinical practice data to compare survival rates among women with heart failure with or without a ...
Full textLink to itemCite
Journal ArticleJ Am Coll Cardiol · December 15, 2015
BACKGROUND: Patients with moderate-to-severe chronic kidney disease (CKD) are poorly represented in clinical trials of cardiac resynchronization therapy (CRT). OBJECTIVES: This study sought to assess the real-world comparative effectiveness of CRT with def ...
Full textLink to itemCite
Journal ArticleEur Heart J · December 7, 2015
AIM: To assess clinical outcomes, efficacy, and safety according to sex during anticoagulation with apixaban compared with warfarin in patients with atrial fibrillation. METHODS AND RESULTS: Apixaban for Reduction in Stroke and Other Thromboembolic Events ...
Full textLink to itemCite
Journal ArticleJ Gen Intern Med · December 2015
BACKGROUND: Although the implantable cardioverter-defibrillator (ICD) is highly effective therapy for preventing sudden cardiac death, there is considerable uncertainty about its benefits and harms in older patients, especially in the presence of factors, ...
Full textLink to itemCite
Journal ArticleClin Trials · October 2015
Pragmatic clinical trials are designed to inform decision makers about the benefits, burdens, and risks of health interventions in real-world settings. Pragmatic clinical trials often use for research purposes data collected in the course of clinical pract ...
Full textLink to itemCite
Journal ArticleClin Trials · October 2015
Pragmatic clinical trials can help answer questions of comparative effectiveness for interventions routinely used in medical practice. Pragmatic clinical trials may examine outcomes of one or more marketed medical products, and they are heterogeneous in de ...
Full textLink to itemCite
Journal ArticleCard Electrophysiol Clin · September 2015
An implantable-cardioverter defibrillator (ICD) can terminate ventricular arrhythmias by delivering a shock or by antitachycardia pacing (ATP). The ATP works by capturing the excitable gap and disrupting re-entrant ventricular arrhythmias. Multiple studies ...
Full textLink to itemCite
Journal ArticleJ Am Heart Assoc · August 6, 2015
BACKGROUND: Implantable cardioverter-defibrillator (ICD) therapy is associated with improved outcomes in patients with heart failure (HF), but whether this association holds among older patients with multiple comorbid illnesses and worse HF burden remains ...
Full textOpen AccessLink to itemCite
Journal ArticleHeart Rhythm · July 2015
BACKGROUND: The number of cardiac implantable electronic device (CIED) recalls and advisories has increased over the past 3 decades, yet no consensus exists on how to best manage patients with these CIEDs, partially because rates of complications from prop ...
Full textLink to itemCite
Journal ArticleJAMA · June 23, 2015
IMPORTANCE: Implantable cardioverter-defibrillators (ICDs) are not recommended within 40 days of myocardial infarction (MI); thus, ICD implantation might not be considered during the post-MI care transition. OBJECTIVE: To examine ICD implantation rates and ...
Full textLink to itemCite
Journal ArticleNephrol Dial Transplant · May 2015
BACKGROUND: Sudden cardiac death is the leading cause of death among end-stage kidney disease patients (ESKD) on dialysis, but the benefit of primary prevention implantable cardioverter defibrillators (ICDs) in this population is uncertain. We conducted th ...
Full textLink to itemCite
Journal ArticleCirc Cardiovasc Qual Outcomes · May 2015
BACKGROUND: Antiarrhythmic drugs (AADs) are used to reduce the frequency, severity, and duration of atrial fibrillation (AF) events, which should reduce hospitalizations; however, little is known about the associations between different AADs and hospitaliz ...
Full textLink to itemCite
Journal ArticleCirc Cardiovasc Qual Outcomes · March 2015
BACKGROUND: The impact of patient age on the risks of death or rehospitalization after primary prevention implantable cardioverter-defibrillator (ICD) placement is uncertain. METHODS AND RESULTS: Data from 5 major ICD trials were merged: the Multicenter Au ...
Full textLink to itemCite
Journal ArticleEur Heart J Acute Cardiovasc Care · February 2015
AIMS: Establishing epicardial flow with percutaneous coronary intervention (PCI) for ST-segment elevation myocardial infarction (STEMI) is necessary but not sufficient to ensure nutritive myocardial reperfusion. We evaluated whether adding myocardial blush ...
Full textLink to itemCite
Journal ArticleJ Cardiovasc Electrophysiol · February 2015
INTRODUCTION: We conducted this pilot randomized clinical trial to determine the feasibility of a large clinical trial aimed at testing whether early use of catheter ablation of ventricular tachycardia (VT) is superior to antiarrhythmic medications at redu ...
Full textLink to itemCite
Journal ArticleAm J Cardiol · February 1, 2015
Little is known in clinical practice about antiarrhythmic drug (AAD) use in patients with atrial fibrillation (AF) (particularly younger ones) who do not have structural heart disease. Using the MarketScan database, we identified patients <65 years without ...
Full textLink to itemCite
Journal ArticleJACC Heart Fail · February 2015
OBJECTIVES: The purpose of this study was to assess the benefit of primary prevention implantable cardioverter defibrillators (ICDs) in women. BACKGROUND: Clinical trials of primary prevention ICDs enrolled a limited number of women. METHODS: Using a prope ...
Full textLink to itemCite
Journal ArticleCirc Arrhythm Electrophysiol · February 2015
BACKGROUND: Racial and ethnic minorities are under-represented in clinical trials of primary prevention implantable cardioverter-defibrillators (ICDs). This analysis investigates the association between primary prevention ICDs and mortality among Medicare, ...
Full textLink to itemCite
Journal ArticleAm Heart J · January 2015
BACKGROUND: There is no universally accepted algorithm for identifying atrial fibrillation (AF) patients and stroke risk using electronic data for use in performance measures. METHODS: Patients with AF seen in clinic were identified based on International ...
Full textLink to itemCite
Journal ArticleInt J Cardiol · December 20, 2014
BACKGROUND: Although the implantable cardioverter defibrillator (ICD) improves the survival of patients at increased risk of sudden cardiac death due to systolic heart failure, ICD shocks have been associated with both worse survival and quality of life. W ...
Full textLink to itemCite
Journal ArticleBlood · December 11, 2014
Using data from ARISTOTLE, we describe the periprocedural management of anticoagulation and rates of subsequent clinical outcomes among patients chronically anticoagulated with warfarin or apixaban. We recorded whether (and for how long) anticoagulant ther ...
Full textLink to itemCite
Journal ArticleJACC Heart Fail · December 2014
OBJECTIVES: The aim of this study was to determine if the benefit of implantable cardioverter-defibrillators (ICDs) is modulated by medical comorbidity. BACKGROUND: Primary prevention ICDs improve survival in patients at risk for sudden cardiac death. Thei ...
Full textLink to itemCite
ConferenceCirc Heart Fail · November 2014
BACKGROUND: Cardiac resynchronization therapy with defibrillator (CRT-D) reduces morbidity and mortality among selected patients with heart failure in clinical trials. The effectiveness of this therapy in clinical practice has not been well studied. METHOD ...
Full textLink to itemCite
Journal ArticleJ Am Coll Cardiol · October 14, 2014
BACKGROUND: Amiodarone is an effective medication in preventing atrial fibrillation (AF), but it interferes with the metabolism of warfarin. OBJECTIVES: This study sought to examine the association of major thrombotic clinical events and bleeding with the ...
Full textLink to itemCite
Journal ArticleCirc Arrhythm Electrophysiol · October 2014
BACKGROUND: Guidelines recommend that implantable cardioverter-defibrillator (ICD) candidates have an estimated longevity of ≥1 year. Longevity can be affected by chronic kidney disease (CKD). METHODS AND RESULTS: Using the National Cardiovascular Data Reg ...
Full textLink to itemCite
Journal ArticleCirculation · September 23, 2014
BACKGROUND: The rate of implantable cardioverter-defibrillator (ICD) infections has been increasing faster than that of implantation. We sought to determine the rate and predictors of ICD infection in a large cohort of Medicare patients. METHODS AND RESULT ...
Full textLink to itemCite
Journal ArticleAm J Cardiol · September 1, 2014
Sotalol is a commonly prescribed antiarrhythmic drug (AAD) used for maintaining sinus rhythm in patients with atrial fibrillation (AF). Although randomized studies have found that sotalol can significantly delay time to AF recurrence, its association with ...
Full textLink to itemCite
Journal ArticleAm Heart J · September 2014
Approximately half of patients with atrial fibrillation and with risk factors for stroke are not treated with oral anticoagulation (OAC), whether it be with vitamin K antagonists (VKAs) or novel OACs (NOACs); and of those treated, many discontinue treatmen ...
Full textOpen AccessLink to itemCite
Journal ArticleCirc Cardiovasc Qual Outcomes · September 2014
BACKGROUND: Patients with heart failure and atrial fibrillation are at higher risk of thromboembolic events than patients with heart failure alone. Yet, the use of anticoagulation therapy varies in clinical practice, especially among older patients, for wh ...
Full textLink to itemCite
Journal ArticleJ Am Coll Cardiol · July 22, 2014
BACKGROUND: Defibrillation testing is often performed to establish effective arrhythmia termination, but predictors and consequences of an inadequate defibrillation safety margin (DSM) remain largely unknown. OBJECTIVES: The aims of this study were to deve ...
Full textLink to itemCite
Journal ArticleAm J Kidney Dis · July 2014
BACKGROUND: The benefit of a primary prevention implantable cardioverter-defibrillator (ICD) among patients with chronic kidney disease is uncertain. STUDY DESIGN: Meta-analysis of patient-level data from randomized controlled trials. SETTING & POPULATION: ...
Full textLink to itemCite
Journal ArticleEur Heart J · June 7, 2014
Atrial fibrillation (AF) is generally considered a progressive disease, typically evolving from paroxysmal through persistent to 'permanent' forms, a process attributed to electrical and structural remodelling related to both the underlying disease and AF ...
Full textLink to itemCite
Journal ArticleJAMA · June 4, 2014
IMPORTANCE: Clinical trials of prophylactic implantable cardioverter-defibrillators (ICDs) have included a minority of patients with a left ventricular ejection fraction (LVEF) between 30% and 35%. Because a large number of ICDs in the United States are im ...
Full textLink to itemCite
Journal ArticleAnn Intern Med · June 3, 2014
BACKGROUND: The comparative effectiveness of treatments for atrial fibrillation (AF) is uncertain. PURPOSE: To evaluate the comparative effectiveness of rate- and rhythm-control therapies. DATA SOURCES: English-language studies in PubMed, EMBASE, and the C ...
Full textLink to itemCite
Journal ArticleAnn Intern Med · May 6, 2014
BACKGROUND: Trials comparing implantable cardioverter-defibrillator (ICD) therapy with cardiac resynchronization therapy with a defibrillator (CRT-D) are limited to selected patients treated at centers with extensive experience. OBJECTIVE: To compare outco ...
Full textLink to itemCite
Journal ArticleJ Thromb Thrombolysis · April 2014
Warfarin use in patients with acute myocardial infarction (AMI) and atrial fibrillation (AF) remains challenging. We describe use of warfarin up to 1 year after hospitalization among patients with AMI and AF according to stroke and bleeding risk, and ident ...
Full textLink to itemCite
Journal ArticleJ Am Coll Cardiol · March 25, 2014
OBJECTIVES: The aim of this study was to determine the risk of major clinical and thromboembolic events after cardioversion for atrial fibrillation in subjects treated with apixaban, an oral factor Xa inhibitor, compared with warfarin. BACKGROUND: In patie ...
Full textLink to itemCite
Journal ArticleJ Am Coll Cardiol · March 4, 2014
OBJECTIVES: To better inform patients and physicians of the expected risk of adverse events and to assist hospitals' efforts to improve the outcomes of patients undergoing implantable cardioverter-defibrillator (ICD) implantation, we developed and validate ...
Full textLink to itemCite
Journal ArticleJAMA Intern Med · February 1, 2014
IMPORTANCE: Prompt bystander cardiopulmonary resuscitation (CPR) improves the likelihood of surviving an out-of-hospital cardiac arrest. Large regional variations in survival after an out-of-hospital cardiac arrest have been noted. OBJECTIVES: To determine ...
Full textLink to itemCite
Journal ArticleJ Card Fail · January 2014
BACKGROUND: Postdischarge adherence and long-term persistence in the use of warfarin among patients with heart failure and atrial fibrillation without contraindications have not been fully described. METHODS AND RESULTS: We identified patients with heart f ...
Full textLink to itemCite
Journal ArticleJ Atr Fibrillation · 2014
Little is known about the use of pharmacologic rhythm or rate control in younger atrial fibrillation (AF) patients in clinical practice. Using commercial health data from 2006 through 2010, patients aged <65 years with an initial AF encounter were categori ...
Link to itemCite
Journal ArticleJ Atr Fibrillation · 2014
Little is known about the use of pharmacologic rhythm or rate control in younger atrial fibrillation (AF) patients in clinical practice. Using commercial health data from 2006 through 2010, patients aged <65 years with an initial AF encounter were categori ...
Full textLink to itemCite
Journal ArticleCirculation · December 17, 2013
BACKGROUND: Understanding temporal differences in the incidence and outcomes of out-of-hospital cardiac arrest (OHCA) has important implications for developing preventative strategies and optimizing systems for OHCA care. METHODS AND RESULTS: We studied 18 ...
Full textLink to itemCite
Journal ArticlePacing Clin Electrophysiol · December 2013
BACKGROUND: Advances in implantable cardioverter defibrillator (ICD) technology have resulted in more effective defibrillation, and the need for defibrillation threshold (DFT) testing has been questioned. METHODS: A total of 64,227 initial ICD implant proc ...
Full textLink to itemCite
Journal ArticleEuropace · November 2013
The management of atrial fibrillation (AF) has seen marked changes in past years, with the introduction of new oral anticoagulants, new antiarrhythmic drugs, and the emergence of catheter ablation as a common intervention for rhythm control. Furthermore, n ...
Full textLink to itemCite
Journal ArticleAm Heart J · November 2013
BACKGROUND: Atrial fibrillation (AF) guideline recommendations for antiarrhythmic drugs (AADs) are based on the effectiveness and safety of the AAD in patients with selected, concomitant heart disease. It is unknown to what extent these recommendations are ...
Full textLink to itemCite
Journal ArticleExpert Rev Cardiovasc Ther · September 2013
Atrial fibrillation (AF) is associated with significant mortality and morbidity, and stroke represents the most-feared complication. Consequently, AF treatment has focused on thromboprophylaxis, with warfarin as the mainstay of therapy. However, concerns o ...
Full textLink to itemCite
Journal ArticleJAMA · August 14, 2013
IMPORTANCE: The benefits of cardiac resynchronization therapy (CRT) in clinical trials were greater among patients with left bundle-branch block (LBBB) or longer QRS duration. OBJECTIVE: To measure associations between QRS duration and morphology and outco ...
Full textLink to itemCite
Journal ArticleEur Heart J · August 2013
AIMS: It is uncertain whether the benefit from apixaban varies by type and duration of atrial fibrillation (AF). METHODS AND RESULTS: A total of 18 201 patients with AF [2786 (15.3%) with paroxysmal and 15 412 (84.7%) with persistent or permanent] were ran ...
Full textLink to itemCite
Journal ArticleHeart Rhythm · August 2013
BACKGROUND: A 2008 expert consensus statement recommended an in-person follow-up visit between 2 and 12 weeks after the placement of a new cardiovascular implantable electronic device (CIED). OBJECTIVE: To assess outcomes associated with adherence to the e ...
Full textLink to itemCite
Journal ArticleAm Heart J · July 2013
BACKGROUND: Black individuals eligible for an implantable cardioverter/defibrillator (ICD) are considerably less likely than white individuals to receive one. This disparity may, in part, be explained by racial differences in patient preferences. We hypoth ...
Full textLink to itemCite
Journal ArticleCirculation · June 4, 2013
BACKGROUND: In the Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation (ARISTOTLE) trial, apixaban compared with warfarin reduced stroke and systemic embolism, major bleeding, and mortality. We evaluated treatment effect ...
Full textLink to itemCite
Journal ArticleJ Cardiovasc Electrophysiol · June 2013
INTRODUCTION: Practice guidelines recommend the use of ICDs in patients with heart failure (HF) and a left ventricular ejection fraction (LVEF) of ≤ 35% in the absence of contraindications. METHODS AND RESULTS: We performed an analysis of ICD use among pat ...
Full textLink to itemCite
Journal ArticleHeart Rhythm · June 2013
BACKGROUND: Whether there is an optimal time to place an implantable cardioverter-defibrillator (ICD) more than 40 days after myocardial infarction (MI) in guideline-eligible patients is unknown. OBJECTIVE: To evaluate the effect of time from MI to randomi ...
Full textLink to itemCite
Journal ArticleAm Heart J · June 2013
Sudden cardiac arrest (SCA) is one of the most impactful public health problems in the United States. Despite the progress made in reducing the number of cardiac deaths, the incidence of sudden cardiac death remains high. Studies of life-saving interventio ...
Full textLink to itemCite
Journal ArticleCirc Heart Fail · May 2013
BACKGROUND: We examined the risk of stroke or systemic embolism (SSE) conferred by heart failure (HF) and left ventricular systolic dysfunction (LVSD) in the Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation Trial (ARI ...
Full textLink to itemCite
Journal ArticleCirc Arrhythm Electrophysiol · April 2013
BACKGROUND: Although cardiac resynchronization therapy (CRT) can improve left ventricular ejection fraction (LVEF), it is not known whether a specific level of improvement will predict future implantable cardioverter defibrillator (ICD) therapy. METHODS AN ...
Full textLink to itemCite
Journal ArticleJ Interv Card Electrophysiol · March 2013
The drastic changes in the American health-care environment have brought forward several major quality improvement initiatives including performance measurement, the demand for transparency to be implemented, at least in part, through public reporting, and ...
Full textLink to itemCite
Journal ArticleCurr Cardiol Rep · February 2013
The impact of cardiac resynchronization therapy (CRT) on atrial fibrillation (AF) burden is poorly characterized. To assess the influence of CRT on AF, we performed a systematic literature search in MEDLINE using the MeSH headings "cardiac resynchronizatio ...
Full textLink to itemCite
Journal ArticleCirc Arrhythm Electrophysiol · February 2013
BACKGROUND: A 2008 expert consensus statement outlined the minimum frequency of follow-up of patients with cardiovascular implantable electronic devices (CIEDs). METHODS AND RESULTS: We studied 38 055 Medicare beneficiaries who received a new CIED between ...
Full textOpen AccessLink to itemCite
Journal ArticleJAMA · January 2, 2013
IMPORTANCE: Randomized clinical trials have shown that implantable cardioverter-defibrillator (ICD) therapy saves lives. Whether the survival of patients who received an ICD in primary prevention clinical trials differs from that of trial-eligible patients ...
Full textLink to itemCite
Journal ArticlePatient Prefer Adherence · 2013
BACKGROUND: Conveying contemporary treatment options for those at risk of sudden cardiac arrest (SCA) is challenging. The purpose of the present research was to evaluate the quality and usability of available patient educational tools relevant to SCA and i ...
Full textOpen AccessLink to itemCite
Journal ArticleCardiol J · 2013
BACKGROUND: Atrial fibrillation (AF) and chronic kidney disease (CKD) have both been shown to portend worse outcomes after acute myocardial infarction (MI); however, the benefit of a rhythm control strategy in patients with CKD post-MI is unclear. METHODS: ...
Full textLink to itemCite
Journal ArticleLancet · November 17, 2012
BACKGROUND: The Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation (ARISTOTLE) trial showed that apixaban is better than warfarin at prevention of stroke or systemic embolism, causes less bleeding, and results in lower ...
Full textLink to itemCite
Journal ArticleAm Heart J · November 2012
BACKGROUND: Several studies based on claims data have reported underutilization of evidence-based heart failure (HF) therapies. The degree to which these estimates fail to account for therapeutic contraindications is unclear. METHODS: We identified patient ...
Full textLink to itemCite
Journal ArticleClin Cardiol · November 2012
BACKGROUND: Warfarin use and associated outcomes in patients with heart failure and atrial fibrillation and a cardiovascular implantable electronic device have not been described previously. HYPOTHESIS: We hypothesized that warfarin is underused and is ass ...
Full textLink to itemCite
Journal ArticleAm Heart J · September 2012
Atrial fibrillation (AF) represents a growing public health burden. It is a complex condition, involving a number of etiologic factors and arrhythmia mechanisms associated with atrial remodeling. Greater understanding of these mechanisms may improve therap ...
Full textLink to itemCite
Journal ArticleAm Heart J · September 2012
BACKGROUND: In several studies, prolongation of the corrected QT (QTc) interval has been associated with an increased risk of cardiac events. However, data on race and gender variation in the QTc and its associated risk of death are lacking. METHODS: We pr ...
Full textLink to itemCite
Journal ArticleCirculation · July 3, 2012
BACKGROUND: Ventricular arrhythmias remain a lethal complication of acute coronary syndromes (ACS). However, the incidence and prognosis of sustained ventricular tachycardia/ventricular fibrillation (VT/VF) in contemporary non-ST-segment-elevation (NSTE) A ...
Full textLink to itemCite
Journal ArticleCirculation · March 6, 2012
BACKGROUND: Prior studies have demonstrated low use of implantable cardioverter defibrillators (ICDs) as primary prevention, particularly among women and blacks. The degree to which the overall use of ICD therapy and disparities in use have changed is uncl ...
Full textLink to itemCite
Journal ArticleCurr Cardiol Rep · February 2012
Randomized clinical trials have conclusively demonstrated that warfarin prevents stroke in patients with atrial fibrillation. This evidence led the American College of Cardiology, the American Heart Association, and the European Society of Cardiology to de ...
Full textLink to itemCite
Journal ArticleJ Interv Card Electrophysiol · December 2011
In recent years, electrophysiology clinical research has made tremendous progress. Not only have the standards for conducting research and assessing clinical outcomes improved substantially, but the power of well-conducted and designed randomized clinical ...
Full textLink to itemCite
Journal ArticleCardiac Electrophysiology Clinics · December 1, 2011
The registry was developed through a partnership of the Heart Rhythm Society and American College of Cardiology Foundation using the expertise of the National Cardiovascular Data Registry. All hospitals in the United States that implant implantable cardiov ...
Full textCite
Journal ArticleEuropace · December 2011
AIMS: Chronic kidney disease (CKD) is increasingly prevalent, and is an independent risk factor for cardiovascular mortality. Clinical trials of the implantable cardioverter-defibrillator (ICD) have demonstrated a survival benefit over medical therapy for ...
Full textLink to itemCite
Journal ArticleAm Heart J · August 2011
Sudden cardiac arrest (SCA) is the most common cause of death in the United States. Despite national guidelines, patients at risk for SCA often fail to receive evidence-based therapies. Racial and ethnic minorities and women are at particularly high risk f ...
Full textLink to itemCite
Journal ArticleJ Card Fail · April 2011
INTRODUCTION: This study was designed to determine if physicians' attitudes and recommendations surrounding implantable cardioverter-defibrillators (ICDs) are regionally associated with ICD use. METHODS AND RESULTS: A national sample of 9969 members of the ...
Full textLink to itemCite
Journal ArticleHeart Rhythm · March 2011
BACKGROUND: The implantable cardioverter-defibrillator (ICD) is an effective therapy for preventing sudden cardiac death (SCD) in patients with prior myocardial infarction (MI) and reduced left ventricular function; however, the optimal timing of ICD impla ...
Full textLink to itemCite
Journal ArticleCirc Cardiovasc Qual Outcomes · March 2011
BACKGROUND: Several studies that used claims and registry data have reported that 40% to 80% of patients eligible for an implantable cardioverter defibrillator (ICD) fail to receive one in clinical practice, and the rates are especially high among women an ...
Full textLink to itemCite
Journal ArticleJ Am Coll Cardiol · February 15, 2011
The need for consistent and current data describing the true incidence of sudden cardiac arrest (SCA) and/or sudden cardiac death (SCD) was highlighted during the most recent Sudden Cardiac Arrest Thought Leadership Alliance's (SCATLA) Think Tank meeting o ...
Full textLink to itemCite
Journal ArticleJAMA · January 5, 2011
CONTEXT: Practice guidelines do not recommend use of an implantable cardioverter-defibrillator (ICD) for primary prevention in patients recovering from a myocardial infarction or coronary artery bypass graft surgery and those with severe heart failure symp ...
Full textLink to itemCite
Journal ArticleCardiol J · 2011
BACKGROUND: Randomized clinical trials (RCTs) have demonstrated the efficacy of implantable cardioverter-defibrillators (ICDs) in reducing sudden cardiac death (SCD) in specific patient populations. However, patients ≥ 65 years were under-represented in th ...
Full textLink to itemCite
Journal ArticleAnn Noninvasive Electrocardiol · January 2011
BACKGROUND: Implantable cardioverter defibrillator (ICD) therapy improves survival of patients with systolic heart failure. We assessed whether physicians' recommendation for ICD therapy varies as a function of patient age, gender, race, and physician's sp ...
Full textLink to itemCite
Journal ArticleAm Heart J · October 2010
Sudden cardiac arrest (SCA) is the most common cause of death in the Unites States. Despite its major impact on public health, significant challenges exist at the patient, provider, public, and policy levels with respect to raising more widespread awarenes ...
Full textLink to itemCite
Journal ArticleCardiovasc Ther · October 2010
Surgical or modified Maze procedures have been promoted to treat atrial fibrillation (AF); however, few randomized controlled clinical trials (RCTs) examine their outcomes. The purpose of this meta-analysis is to compare the efficacy of surgical Maze proce ...
Full textLink to itemCite
Journal ArticleAm Heart J · October 2010
Although several randomized clinical trials have demonstrated the safety and efficacy of catheter ablation of atrial fibrillation (AF) in experienced centers, the outcomes of this procedure in routine clinical practice and in patients with persistent and l ...
Full textLink to itemCite
Journal ArticleEuropace · August 2010
AIMS: We sought to assess the relation between time from myocardial infarction (MI) to enrolment and patient outcomes and to examine the association between these outcomes and implantable cardioverter defibrillator (ICD) therapy. METHODS AND RESULTS: We an ...
Full textLink to itemCite
Journal ArticleJ Am Coll Cardiol · July 13, 2010
OBJECTIVES: The aim of this study was to determine whether single-photon emission computed tomography (SPECT) myocardial perfusion imaging (MPI) is an effective method of risk stratification for sudden cardiac death (SCD) in patients with coronary artery d ...
Full textLink to itemCite
Journal ArticleAm Heart J · July 2010
BACKGROUND: More than 80% of sudden cardiac deaths (SCDs) occur in patients >or=65 years old; the cost-effectiveness of implantable cardioverter defibrillator (ICD) therapy in older patients remains unclear. We sought to examine the cost-effectiveness of I ...
Full textLink to itemCite
Journal ArticleJ Cardiovasc Electrophysiol · July 2010
BACKGROUND: The optimal timing of implantable cardioverter defibrillator (ICD) placement for the primary prevention of sudden cardiac death after myocardial infarction (MI) remains unknown. METHODS AND RESULTS: We developed a Markov model to investigate th ...
Full textLink to itemCite
Journal ArticleAnn Noninvasive Electrocardiol · July 2010
BACKGROUND: Although no clinical trial data exist on the optimal management of atrial fibrillation (AF) in patients with diastolic heart failure, it has been hypothesized that rhythm-control is more advantageous than rate-control due to the dependence of t ...
Full textLink to itemCite
Journal ArticleHeart · June 2010
OBJECTIVE: The management of patients with atrial fibrillation (AF) following a myocardial infarction (MI) remains uncertain. This study compared a rate control strategy to an anti-arrhythmic-based rhythm control strategy for the treatment of AF following ...
Full textLink to itemCite
Journal ArticleJ Cardiovasc Electrophysiol · May 2010
INTRODUCTION: Remote monitoring is increasingly becoming the new standard of care for implantable cardioverter defibrillator (ICD) follow-up. We sought to determine whether remote monitoring of ICDs improves patient outcomes compared with quarterly device ...
Full textLink to itemCite
Journal ArticleJ Am Coll Cardiol · April 27, 2010
OBJECTIVES: We sought to determine the utility of combined heart failure (HF) device diagnostic information to predict clinical deterioration of HF in patients with systolic left ventricular dysfunction. BACKGROUND: Some implantable devices continuously mo ...
Full textLink to itemCite
Journal ArticleAm Heart J · March 2010
Atrial fibrillation (AF) is associated with increased risk of stroke that can be attenuated with vitamin K antagonists (VKAs). Vitamin K antagonist use is limited, in part, by the high incidence of complications when patients' international normalized rati ...
Full textLink to itemCite
Journal ArticleAm J Med · February 2010
BACKGROUND: We examined warfarin use at discharge (according to Congestive heart failure, Hypertension, Age>75 years, Diabetes, Prior Stroke/transient ischemic attack score and bleeding risk) and its association with 6-month death or myocardial infarction ...
Full textLink to itemCite
Journal ArticleEur Heart J · January 2010
AIMS: To determine whether predictors of sudden cardiac death (SCD) vary with time after myocardial infarction (MI). METHODS AND RESULTS: We analysed 11 256 patients enrolled in VALIANT. Landmark analysis and Cox proportional hazards modelling were used to ...
Full textLink to itemCite
Journal ArticleAm Heart J · January 2010
Atrial fibrillation (AF) is a major public health problem in the United States that is associated with increased mortality and morbidity. Of the therapeutic modalities available to treat AF, the use of percutaneous catheter ablation of AF is expanding rapi ...
Full textLink to itemCite
Journal ArticleCirc Heart Fail · January 2010
BACKGROUND: The clinical effectiveness of implantable cardioverter-defibrillators (ICDs) in older patients with heart failure has not been established, and older patients have been underrepresented in previous studies. METHODS AND RESULTS: We identified pa ...
Full textLink to itemCite
Journal ArticleAm J Cardiol · December 15, 2009
The currently available sudden cardiac death (SCD) risk prediction tools fail to identify most at-risk patients and cannot delineate a specific patient's SCD risk. We sought to develop a tool to improve the risk stratification of patients with coronary art ...
Full textLink to itemCite
Journal ArticleCirc Arrhythm Electrophysiol · December 2009
BACKGROUND: Catheter ablation is an established yet evolving nonpharmacologic intervention for the maintenance of sinus rhythm in patients with atrial fibrillation (AF). The efficacy and safety of pulmonary vein isolation (PVI) compared with medical therap ...
Full textLink to itemCite
Journal ArticleAm Heart J · November 2009
BACKGROUND: Current practice related to the management of atrial fibrillation (AF) complicating coronary artery bypass grafting (CABG) is uncertain. METHODS: We examined management of post-CABG AF in the PREVENT-IV trial, and we explored patterns of use of ...
Full textLink to itemCite
Journal ArticleKidney Int · September 2009
Sudden cardiac death is the most common cause of mortality among patients with end-stage kidney disease maintained on hemodialysis. To examine whether this increased risk is also seen with less advanced kidney disease, we studied the relationship between g ...
Full textLink to itemCite
Journal ArticleAnn Pharmacother · July 2009
BACKGROUND: Implantable cardioverter defibrillators (ICDs) are indicated for both primary and secondary prevention of sudden cardiac arrest. beta-Blockers are also indicated in most patients who have an indication for an ICD; however, their use in this pop ...
Full textLink to itemCite
Journal ArticleEur Heart J · April 2009
Aims Successful epicardial reperfusion with primary percutaneous coronary intervention (PCI) for ST-elevation myocardial infarction (STEMI) can paradoxically evoke myocardial reperfusion injury, which may be signalled by temporally associated ventricular a ...
Full textLink to itemCite
Journal ArticleJ Am Coll Cardiol · February 3, 2009
OBJECTIVES: The aim of this study was to describe hospital variation and factors associated with adherence to guidelines for implantable cardioverter-defibrillator (ICD) therapy. BACKGROUND: Studies have shown incomplete application of ICD therapy in eligi ...
Full textLink to itemCite
Journal ArticleCirc Cardiovasc Imaging · November 2008
BACKGROUND: Single-photon emission computed tomography myocardial perfusion imaging defects are associated with increased all-cause mortality and cardiovascular death. However, it is unknown whether single-photon emission computed tomography myocardial per ...
Full textLink to itemCite
Journal ArticleCirc Arrhythm Electrophysiol · October 2008
BACKGROUND: Little is known about factors that influence survival and complications after implantable cardioverter-defibrillator (ICD) implantation in routine clinical practice. We examined patient and implanting physician factors associated with outcomes ...
Full textLink to itemCite
Journal ArticleJ Cardiovasc Electrophysiol · October 2008
INTRODUCTION: We conducted this study to examine the effect of the ICD on the outcomes of patients with prior coronary revascularization enrolled in the Sudden Cardiac Death in Heart Failure Trial (SCD-HeFT) and to assess the association of time from coron ...
Full textLink to itemCite
Journal ArticleAm Heart J · October 2008
Because the burden of sudden cardiac death (SCD) is substantial, it is important to use all guideline-driven therapies to prevent SCD. Among those therapies is the implantable cardioverter defibrillator (ICD). When indicated, ICD use is beneficial and cost ...
Full textLink to itemCite
Journal ArticleEuropace · August 2008
AIMS: We sought to define reperfusion-induced ventricular arrhythmias (VAs) more precisely through simultaneous angiography, continuous ST-segment recovery, and beat-to-beat Holter analyses in subjects with anterior ST-elevation myocardial infarction (STEM ...
Full textLink to itemCite
Journal ArticleHeart · July 2008
OBJECTIVE: To assess variables associated with the occurrence of atrial fibrillation (AF) and the relation of AF with short- and long-term outcomes and with other in-hospital complications in patients with acute coronary syndromes (ACS) with and without ST ...
Full textLink to itemCite
Journal ArticleAm J Cardiol · April 15, 2008
Little is presently known regarding whether a rhythm-control or a rate-control strategy is more frequently used in patients hospitalized for atrial fibrillation (AF). This study was conducted to assess patient and physician characteristics associated with ...
Full textLink to itemCite
Journal ArticleAm Heart J · January 2008
BACKGROUND: We sought to assess the association of amiodarone use with mortality during consecutive periods in patients with post-acute myocardial infarction with left ventricular systolic dysfunction and/or HF treated with a contemporary medical regimen. ...
Full textLink to itemCite
Journal ArticleJ Cardiovasc Electrophysiol · December 2007
INTRODUCTION: Although it is known that patients with diastolic heart failure are at an increased risk of death, their mode of death has not been clearly defined. We conducted this study to examine the incidence and predictors of sudden cardiac death (SCD) ...
Full textLink to itemCite
Journal ArticleJAMA · October 3, 2007
CONTEXT: Previous studies of sex differences in the use of implantable cardioverter-defibrillators (ICDs) predate recent expansions in Medicare coverage and did not provide patient follow-up over multiple years. OBJECTIVE: To examine sex differences in ICD ...
Full textLink to itemCite
Journal ArticleJAMA · October 3, 2007
CONTEXT: Practice guidelines recommend implantable cardioverter-defibrillator (ICD) therapy for patients with heart failure and left ventricular ejection fraction of 30% or less. The influence of sex and race on ICD use among eligible patients is unknown. ...
Full textLink to itemCite
Journal ArticleAm J Cardiol · September 15, 2007
Age-adjusted sudden cardiac death rates are highest for black patients compared with other racial groups. The prophylactic implantation of an implantable cardioverter-defibrillator (ICD) provides a significant reduction in sudden cardiac death and overall ...
Full textLink to itemCite
Journal ArticleAm Heart J · June 2007
Accurate and timely prediction of sudden cardiac death (SCD) is a necessary prerequisite for effective prevention and therapy. Although the largest number of SCD events occurs in patients without overt heart disease, there are currently no tests that are o ...
Full textLink to itemCite
Journal ArticleAm Heart J · June 2007
Although current evidence supporting a more precise strategy for identifying patients at highest risk for sudden cardiac death (SCD) is sparse, strategies for translating existing and future evidence into clinical practice and policy are needed today. A gr ...
Full textLink to itemCite
Journal ArticleCirculation · July 11, 2006
BACKGROUND: In the Sudden Cardiac Death in Heart Failure Trial (SCD-HeFT), implantable cardioverter-defibrillator (ICD) therapy significantly reduced all-cause mortality rates compared with medical therapy alone in patients with stable, moderately symptoma ...
Full textLink to itemCite
Journal ArticleJ Am Coll Cardiol · October 18, 2005
OBJECTIVES: The purpose of this study is to determine if implantable cardioverter-defibrillator (ICD) implantation should be limited to physicians with high procedural volume. BACKGROUND: Expanding indications for ICDs will result in an increasing number o ...
Full textLink to itemCite
Journal ArticleAm Heart J · June 2005
Although many studies have shown that implantable cardioverter defibrillator (ICD) therapy improves the survival of patients with significant left ventricular dysfunction, the magnitude of effectiveness of ICD therapy in clinically defined subgroups remain ...
Full textLink to itemCite
Journal ArticleJ Gen Intern Med · May 2005
OBJECTIVE: To assess health care practitioners' ability to correctly measure the QT interval, and to identify factors and medications that may increase the risk of QT-interval prolongation and torsades de pointes. DESIGN: A cross-sectional analysis of a su ...
Full textLink to itemCite
Journal ArticleAnn Intern Med · April 19, 2005
BACKGROUND: The Multicenter Automatic Defibrillator Implantation Trial (MADIT)-II demonstrated that implantable cardioverter defibrillators (ICDs) save lives when used in patients with a history of myocardial infarction (MI) and an ejection fraction of 0.3 ...
Full textLink to itemCite
Journal ArticleAm Heart J · April 2005
BACKGROUND: In the fibrinolytic era, several studies have suggested that the rate of atrioventricular block (AVB) in the setting of acute myocardial infarction (MI) is high and is associated with increased short-term mortality. We sought to delineate predi ...
Full textLink to itemCite
Chapter · January 1, 2005
Congestive heart failure (CHF) is a major public health problem which afflicts 5 million Americans.1 A new diagnosis of CHF is made in 400 000 Americans each year.1 CHF is the most common cardiovascular discharge diagnosis in elderly patients. With the agi ...
Full textCite
Journal ArticleAm J Cardiol · September 15, 2004
In 1,009 patients with atrial fibrillation and congestive heart failure, the 2-year mortality rate was 31% in patients treated with rate control (n = 505) versus 29% in patients treated with rhythm control (n = 504). After adjusting for differences in base ...
Full textLink to itemCite
Journal ArticleJAMA · April 23, 2003
CONTEXT: Of the several factors implicated in causing QT interval prolongation and torsades de pointes, errors in the use of medications that may prolong this interval deserve special attention. OBJECTIVE: To systematically summarize the available clinical ...
Full textLink to itemCite
Journal ArticleAnn Noninvasive Electrocardiol · April 2003
BACKGROUND: Recently, some QT-prolonging, noncardiac medications were withdrawn from the U.S. drug market because of continued inappropriate use by health care practitioners despite warnings and label changes from both the drug manufacturers and the U.S. F ...
Full textLink to itemCite
Journal ArticleAm Heart J · March 2003
BACKGROUND: In many patients, ventricular arrhythmias will develop early after acute myocardial infarction. We studied the incidence, timing, and outcomes of such arrhythmias in the international Global Utilization of Streptokinase and TPA (alteplase) for ...
Full textLink to itemCite
Journal ArticleAm J Med · February 1, 2003
Many drugs prolong the QT interval and increase the risk of torsade de pointes. Concurrent use of two or more of these drugs can further increase the risk, but the prevalence of concurrent prescription of QT-prolonging drugs is not known. Using the adminis ...
Full textLink to itemCite
Journal ArticleCirculation · July 16, 2002
BACKGROUND: The prognosis of ventricular arrhythmias among patients with non-ST-elevation acute coronary syndromes is unknown. We studied the incidence, predictors, and outcomes of sustained ventricular arrhythmias in 4 large randomized trials of such pati ...
Full textLink to itemCite
Journal ArticleAm Heart J · July 2000
BACKGROUND: Quantitative data on the frequency with which transition from intermittent to permanent atrial fibrillation occurs are lacking. We conducted this study to determine the proportion of patients with intermittent atrial fibrillation who progress t ...
Full textLink to itemCite
Journal ArticleAm Heart J · September 1999
Wolff-Parkinson-White syndrome is the most common form of ventricular preexcitation. Understanding this syndrome is fundamental for anyone interested in learning about arrhythmias. This review addresses (1) the historic sequence of events that led to the u ...
Full textLink to itemCite